Fosfomycin for MRCoNS Treatment
Fosfomycin is NOT recommended as monotherapy for systemic MRCoNS infections, but may have a role in uncomplicated urinary tract infections caused by susceptible strains or as combination therapy for serious infections when other options are limited.
Key Evidence and Limitations
FDA-Approved Indications
The FDA-approved formulation of oral fosfomycin is only indicated for uncomplicated cystitis in women as a single 3-gram dose 1, 2. There is no FDA approval for systemic MRCoNS infections or for multi-dose regimens.
Microbiological Activity Against CoNS
- Historical data shows fosfomycin had activity against coagulase-negative staphylococci, with 54 of 60 "problem" Gram-positive cocci being susceptible in vitro 3
- However, resistance emerges readily - mutants resistant to fosfomycin were easily demonstrated, though their growth could be prevented by rifampin or ciprofloxacin combinations 3
- Recent surveillance identified a novel chromosomal fosfomycin resistance gene (fosSC) in 53.2% of S. capitis isolates, conferring high-level resistance 4
Critical Resistance Concerns
The emergence of the fosSC gene in over half of S. capitis isolates represents a major threat to fosfomycin utility against CoNS 4. This chromosomal resistance mechanism, combined with the ease of mutational resistance, makes monotherapy particularly problematic.
Clinical Recommendations by Infection Type
Uncomplicated Cystitis (UTI)
- Single 3-gram oral dose is appropriate if the isolate is susceptible 5, 1
- This is the only FDA-approved indication
- Obtain susceptibility testing given rising resistance rates
Systemic/Complicated Infections
Do not use fosfomycin monotherapy. The IDSA MRSA guidelines 6 do not include fosfomycin in their treatment algorithms for:
- Bacteremia
- Endocarditis
- Osteomyelitis
- CNS infections
- Pneumonia
Combination Therapy Considerations
If fosfomycin is considered for systemic MRCoNS (off-label):
- Must be combined with rifampin or another agent to prevent resistance emergence 3
- Dosing for systemic infections requires 6-12 g/day divided into 3 doses (not the single-dose regimen) 7
- For Gram-positive bacteria, 8-12 g/day IV has been suggested 8
- Recent data in S. aureus bacteremia showed adjunctive fosfomycin improved bacterial clearance but increased toxicity (RR 2.03) 9
Preferred Alternatives for MRCoNS
Based on IDSA guidelines 6, first-line agents for methicillin-resistant staphylococcal infections include:
- Vancomycin (15 mg/kg IV every 6-12 hours)
- Daptomycin (6-10 mg/kg IV daily for non-pneumonia infections)
- Linezolid (600 mg PO/IV twice daily)
Critical Pitfalls to Avoid
- Never use single-dose fosfomycin for systemic infections - this is only for uncomplicated cystitis
- Never use fosfomycin monotherapy for serious infections - resistance emerges rapidly 3
- Do not assume susceptibility - obtain MIC testing given the 53% prevalence of fosSC resistance in S. capitis 4
- Recognize the lack of clinical trial data - fosfomycin for systemic CoNS infections is based on limited case reports and in vitro data, not robust clinical trials 10, 8
Bottom Line Algorithm
For MRCoNS infections:
- Uncomplicated cystitis with documented susceptibility → Single 3-gram oral dose acceptable
- Complicated UTI or systemic infection → Use vancomycin, daptomycin, or linezolid as first-line; fosfomycin only as salvage combination therapy with rifampin if other options exhausted
- Always obtain susceptibility testing before considering fosfomycin given emerging resistance